Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2013 1
2017 3
2018 2
2019 2
2020 1
2021 2
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Neuronal-Hematopoietic Cell Fusion in Diabetic Neuropathy.
Terashima T, Katagi M, Ohashi N. Terashima T, et al. Among authors: ohashi n. Stem Cells Transl Med. 2023 Apr 17;12(4):215-220. doi: 10.1093/stcltm/szad015. Stem Cells Transl Med. 2023. PMID: 36976582 Free PMC article.
O-linked N-acetylglucosamine modification is essential for physiological adipose expansion induced by high-fat feeding.
Nakamoto A, Ohashi N, Sugawara L, Morino K, Ida S, Perry RJ, Sakuma I, Yanagimachi T, Fujita Y, Ugi S, Kume S, Shulman GI, Maegawa H. Nakamoto A, et al. Among authors: ohashi n. Am J Physiol Endocrinol Metab. 2023 Jul 1;325(1):E46-E61. doi: 10.1152/ajpendo.00263.2022. Epub 2023 May 24. Am J Physiol Endocrinol Metab. 2023. PMID: 37224467
Microbiome potentiates endurance exercise through intestinal acetate production.
Okamoto T, Morino K, Ugi S, Nakagawa F, Lemecha M, Ida S, Ohashi N, Sato D, Fujita Y, Maegawa H. Okamoto T, et al. Among authors: ohashi n. Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E956-E966. doi: 10.1152/ajpendo.00510.2018. Epub 2019 Mar 12. Am J Physiol Endocrinol Metab. 2019. PMID: 30860879 Free article.
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H; SUMS-ADDIT-2 Research group. Horibe K, et al. Among authors: ohashi n. Diabetes Res Clin Pract. 2022 Apr;186:109781. doi: 10.1016/j.diabres.2022.109781. Epub 2022 Feb 15. Diabetes Res Clin Pract. 2022. PMID: 35181350 Clinical Trial.
22 results